UNAIDS (2014): Report on the Global AID Epidemic. Retrieved from: http://www.data.unaids.org/pub/ GlobalReport/2014.
Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte A'A, Phillips AN, Sabin CA, Lundgren JD (2014) Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: A: D): a multicohort collaboration. The Lancet 384(9939):241–248. https://doi.org/10.1016/S0140-6736(14)60604-8
Article
Google Scholar
Sulkowski MS, Thomas DL (2003) Hepatitis C in the HIV-infected person. Annals of internal medicine 138(3):197–207. https://doi.org/10.7326/0003-4819-138-3-200302040-00012
Article
PubMed
Google Scholar
Ossama Ashraf Ahmed, Eslam Safwat, Mohamed Omar Khalifa et al., Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village. Int J Hepatol. 2018;2018:9616234. doi: 10.1155/2018/9616234.
Gower E, Estes C, Blach S et al (2014) Global Epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61(1)
Bifano M, Hwang C, Oosterhuis B et al (2013) Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 18(7):931–940
Article
CAS
Google Scholar
Grebely J, Hellard M, Applegate T et al (2012) Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS (London, England) 26(13):1653
Article
CAS
Google Scholar
Monje-Agudo A, Castro-Iglesias A, Rivero-Juárez et al (2015) Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. Eurobian J Clin Microbiol Infect Dis:1929–1936
Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC Jr, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P (2015) Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. New England J Med 373(8):714–725. https://doi.org/10.1056/NEJMoa1503153
Article
CAS
Google Scholar
Milazzo L, Lai A, Calvi E, Ronzi P, Micheli V, Binda F, Ridolfo AL, Gervasoni C, Galli M, Antinori S, Sollima S (2017) Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. HIV Med 18(4):284–291. https://doi.org/10.1111/hiv.12429
Article
CAS
PubMed
Google Scholar
Hézode C, Abergel A, Chas J, Conti F, Cotte L, Tateo M, Alric L, Vergniol J, Tomei C, Bernard PH, Loustaud-Ratti V, Arpurt JP, Blaison D, Larrey D, Fedchuk L, Bennai Y, Filipovics A, Fontaine H, Pageaux GP (2016) Sustained virologic response to daclatasvir and sofosbuvir, with or without ribavirin, among patients in the French daclatasvir ATU programme infected with HCV genotypes 4, 5 and 6. J Hepatol 64(2):S755. https://doi.org/10.1016/S0168-8278(16)01471-9
Article
Google Scholar
Garimella T, You X, Wang R, Huang SP, Kandoussi H, Bifano M, Bertz R, Eley T (2016) A review of daclatasvir drug–drug interactions. Adv Ther 33(11):1867–1884. https://doi.org/10.1007/s12325-016-0407-5
Article
CAS
PubMed
PubMed Central
Google Scholar
Panel Chung RT, Davis GL, Jensen DM et al (2015) Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62(3):932–954
Article
Google Scholar
Dazley J, Sison R, Slim J (2015) Long-Term Consequences of Hepatitis C Viral Clearance on the CD4. AIDS Res Treat 2015:1–4. https://doi.org/10.1155/2015/687629
Article
Google Scholar
Sarah M Michienzi, Jiaqi Cai, Cydnee Harris, et al., HIV-HCV Coinfection: An Investigation of CD4 T-Cell Reconstitution after HCV Direct-Acting Antiviral Treatment. Open Forum Infect Dis. 2019; 6(Suppl 2): S187.Published online 2019 Oct 23. doi: https://doi.org/10.1093/ofid/ofz360.429
Braitstein P, Zala C, Yip B, Brinkhof MWG, Moore D, Hogg RS, Montaner JSG (2006) Immunologic response to antiretroviral therapy in hepatitis C virus– coinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis 193(2):259–268. https://doi.org/10.1086/498908
Article
CAS
PubMed
Google Scholar
Elsharkawy A, Alem SA, Fouad R, el Raziky M, el Akel W, Abdo M, Tantawi O, AbdAllah M, Bourliere M, Esmat G (2017) Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. J Gastroenterol Hepatol 32(9):1624–1630. https://doi.org/10.1111/jgh.13758
Article
CAS
PubMed
Google Scholar
Bachofner JA, Valli PV, Kröger A, Bergamin I, Künzler P, Baserga A, Braun D, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Müllhaupt B, Terziroli Beretta-Piccoli B, Mertens JC (2017) Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase platelet ratio index. Liver Int 37(3):369–376. https://doi.org/10.1111/liv.13256
Article
CAS
PubMed
Google Scholar
Mehta R, Kabrawala M, Nandwani S et al (2017) Safety and efficacy of sofosbuvir and daclatasvir for hepatitis C virus infection in patients with β-thalassemia major. J Clin Exper Hepatol
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England J Med 370(3):211–221. https://doi.org/10.1056/NEJMoa1306218
Article
CAS
Google Scholar
Molina J, Chloe O, David MI et al (2015) Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients coinfected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. The Lancet 385(9973):1098–1106. https://doi.org/10.1016/S0140-6736(14)62483-1
Article
CAS
Google Scholar
Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison J, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M, ION-4 Investigators (2015) Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV1. New England J Med 373(8):705–713. https://doi.org/10.1056/NEJMoa1501315
Article
CAS
Google Scholar